Ratings Suven Pharmaceuticals Limited Bombay S.E.

Equities

SUVENPHAR

INE03QK01018

Delayed Bombay S.E. Other stock markets 12:38:41 2024-04-30 am EDT			5-day change	1st Jan Change
645.8 ^INR	+0.21%		+0.30%	-11.07%

Mar. 27	Suven Pharmaceuticals Limited Announces Shifting of Registered Office	CI
Mar. 05	Transcript : Cohance Lifesciences Limited, Suven Pharmaceuticals Limited - M&A Call

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 40.68 times its estimated earnings per share for the ongoing year.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is not the most generous with respect to shareholders' compensation.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
SUVEN PHARMACEUTICALS LIMITED	-11.07%	1.99B	D-
ELI LILLY AND COMPANY	+26.47%	664B	C+
NOVO NORDISK A/S	+26.74%	567B	B
JOHNSON & JOHNSON	-6.33%	354B	C+
MERCK & CO., INC.	+19.35%	330B	B-
ABBVIE INC.	+4.23%	286B	C+
ASTRAZENECA PLC	+13.43%	234B	B+
NOVARTIS AG	+4.71%	199B	B-
ROCHE HOLDING AG	-9.53%	196B	A+
AMGEN INC.	-4.04%	148B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes